Therapeutic Drug Monitoring in Tuberculosis: Practical Application for Physicians.

about

Intestinal tuberculosis: a diagnostic challenge.Reply to Alffenaar et al.

P2860

Q40161720-825C1107-D898-4164-83A3-C31729D4134B Q45237067-8C14BC3A-3A38-4902-A678-7352CDAB1A61

P2860

Therapeutic Drug Monitoring in Tuberculosis: Practical Application for Physicians.

Item

http://www.wikidata.org/entity/Q45046059

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

Therapeutic Drug Monitoring in Tuberculosis: Practical Application for Physicians.

@en

Therapeutic Drug Monitoring in Tuberculosis: Practical Application for Physicians.

@nl

type

Item

label

Therapeutic Drug Monitoring in Tuberculosis: Practical Application for Physicians.

@en

Therapeutic Drug Monitoring in Tuberculosis: Practical Application for Physicians.

@nl

prefLabel

Therapeutic Drug Monitoring in Tuberculosis: Practical Application for Physicians.

@en

Therapeutic Drug Monitoring in Tuberculosis: Practical Application for Physicians.

@nl

P1476

Therapeutic Drug Monitoring in Tuberculosis: Practical Application for Physicians

@en

P2093

Jan-Willem C Alffenaar

http://www.w3.org/2001/XMLSchema#string

Martin P Grobusch

http://www.w3.org/2001/XMLSchema#string

Roger K Verbeeck

http://www.w3.org/2001/XMLSchema#string

Scott K Heysell

http://www.w3.org/2001/XMLSchema#string

P2860

Sensititre MycoTB plate compared to Bactec MGIT 960 for first- and second-line antituberculosis drug susceptibility testing in Tanzania: a call to operationalize MICs.

NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy

Serum drug concentrations predictive of pulmonary tuberculosis outcomes.

Dried blood spots: a new tool for tuberculosis treatment optimization.

Current status and opportunities for therapeutic drug monitoring in the treatment of tuberculosis.

Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.

Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement.

The influence of human N-acetyltransferase genotype on the early bactericidal activity of isoniazid.

End TB with precision treatment!

Incorporating therapeutic drug monitoring into the World Health Organization hierarchy of tuberculosis diagnostics

P304

104-105

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/CID/CIW677

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Simon Tiberi

P577

2016-10-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27789609

http://www.w3.org/2001/XMLSchema#string

P932

6394131

http://www.w3.org/2001/XMLSchema#string

Therapeutic Drug Monitoring in Tuberculosis: Practical Application for Physicians.

about

P2860

P2860

Therapeutic Drug Monitoring in Tuberculosis: Practical Application for Physicians.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932